Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
about
Differential role of RB in response to UV and IR damage.Cell cycle regulation and novel structural features of thymidine kinase, an essential enzyme in Trypanosoma bruceiTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapyKinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyXResistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge cost of fitnessThymidylate synthase expression determines pemetrexed targets and resistance development in tumour cellsStructural Analysis of Thymidylate Synthase from Kaposi's Sarcoma-Associated Herpesvirus with the Anticancer Drug RaltitrexedHow well can morphology assess cell death modality? A proteomics studyPhase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerThe CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1.Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed.A one-step method for quantitative determination of uracil in DNA by real-time PCR.Successful curative resection of gallbladder cancer following S-1 chemotherapy: A case report and review of the literature.Analysis of mRNA recognition by human thymidylate synthase.Effect of the thymidylate synthase inhibitors on dUTP and TTP pool levels and the activities of DNA repair glycosylases on uracil and 5-fluorouracil in DNA.Pharmacogenetics of methotrexate.Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy.Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach.Genetic factors influencing pyrimidine-antagonist chemotherapy.Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics.Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinomaDepletion of deoxyribonucleotide pools is an endogenous source of DNA damage in cells undergoing oncogene-induced senescence.Effects of 5-fluorouracil adjuvant treatment of colon cancer.Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levelsSuppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cellsDNA translocation by human uracil DNA glycosylase: the case of single-stranded DNA and clustered uracils.Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatmentPharmacogenomics in colorectal cancer: the first step for individualized-therapyMechanisms of antifolate resistance and methotrexate efficacy in leukemia cells.Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathwayAntibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells.An aptamer intrinsically comprising 5-fluoro-2'-deoxyuridine for targeted chemotherapy.P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting.Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways.Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent.
P2860
Q24802969-2ABBC434-869E-4284-872A-EFA08FEFAA7DQ27720126-1AE0FB9D-CC73-46EC-A449-509BD2BB6236Q27851526-F6619F61-FFA2-4BB4-A157-A813A0F808C3Q28472798-60E43ECC-185B-429B-9566-A4AA3EBCABD1Q28478613-F9A1B342-E7E7-48D5-BE98-720719AA6820Q28487936-32793B69-4F0F-4164-B541-FE5B4A1A351DQ28554947-1BFE7DE5-2391-4CC9-9C10-A27855A1EEA6Q28822630-5872E487-A517-45C9-8615-27FA000DE61CQ33400687-DC8F17C6-A7E6-4886-866C-AAA7DA22E220Q33986683-87F81D09-71D9-437D-966A-365DBE0B337EQ34099389-0AEFB5F3-26BC-4909-B283-67E1E7C882B9Q34146431-2BAD1092-4531-4F99-BAC1-23D578E076EDQ34255956-AFA5575A-BDF7-403F-995A-D9F12C160674Q34364597-852EE5A0-E35C-45AC-9978-D07A5891FF36Q34368159-45B9DE72-0879-4A13-B756-D83F9DA9B6DCQ34427188-2DFD867F-06F8-470A-B1FF-53828E0E6804Q34761753-4598E1D1-F277-4756-9015-07D926AE7A7CQ34782000-993BC589-FDBE-45AE-A107-B01317A40588Q35911142-0E54C4E8-917D-4C66-95EF-B1A44E38E4C6Q35976422-B9EFAB41-B0AE-4167-8C11-2AA1E00ED932Q36028631-F3914E64-D111-4FD0-9355-0C107ABD2C5FQ36205831-0838F98E-7FC6-479C-9E95-1E62EF704AD9Q36317002-3C0959C3-E06C-413F-87E7-75AFAD13E9A1Q36413366-307C9CD8-0490-4378-B48E-9EE38512B88FQ36495207-31B20969-F117-4A4A-B356-65BB725EDDD3Q36499247-4EB00843-F7CD-48E2-BB9B-8D68C1043FDBQ36609769-446B6D75-9235-46DE-ACF1-B9AADAF26560Q36610029-C015E918-D28B-4211-BC7D-3B4B61A71669Q36643420-4A4D4A65-7F69-4BF2-B00B-69705A57D69EQ36790722-100AA6E9-04F4-4597-8B14-C6FB82C51AD1Q36992444-368B43C7-1F6F-4D60-9155-934092CF3C7AQ36996329-41E57B67-AED9-4AA6-B4C6-6A79450AEEFFQ37093674-581021C9-AC6F-47D2-81CB-095031FFDDDBQ37465949-16DB0ADF-BE3A-428F-8AB3-966900571247Q38290278-2A188CBE-0699-47FB-83B2-B522BF951314Q38304827-E64489C8-3E0E-45F6-B75D-744E172FC8AFQ38603038-AF0AFF3B-8424-41D3-9DA2-FFD52823BD41Q39146524-30E1C333-6599-4CB0-9BFB-E7CDC77E8E20Q39442474-FD59FC59-3EEA-4EEF-92F3-5704526CEDA3Q39924293-8D51AFB9-EBFD-4AC8-ABBC-D60E12FF8CCC
P2860
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Downstream molecular determina ...... ymidylate synthase inhibitors.
@ast
Downstream molecular determina ...... ymidylate synthase inhibitors.
@en
type
label
Downstream molecular determina ...... ymidylate synthase inhibitors.
@ast
Downstream molecular determina ...... ymidylate synthase inhibitors.
@en
prefLabel
Downstream molecular determina ...... ymidylate synthase inhibitors.
@ast
Downstream molecular determina ...... ymidylate synthase inhibitors.
@en
P2093
P356
P1433
P1476
Downstream molecular determina ...... hymidylate synthase inhibitors
@en
P2093
B Van Triest
G J Peters
H M Pinedo
P304
P356
10.1023/A:1008351221345
P577
2000-04-01T00:00:00Z